Health Care·Health Care Equipment·$17.7B
Zimmer Biomet Holdings (ZBH) is a leading company in the health care sector, specializing in medical devices and equipment. The company focuses on products for musculoskeletal health, which are essential for surgeries and treatments related to bones and joints....
EPS
Earnings per share is a key indicator of the company's profitability and financial health.
Revenue
Revenue growth reflects the company's ability to sell its products and expand its market share.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
5Q
EPS Beat Rate
88%
Avg EPS Surprise
+1.73%
Avg Stock Reaction
-2.59%
In the last quarter, Zimmer Biomet reported an EPS of $2.42, exceeding expectations and demonstrating a positive trend in profitability. However, revenue figures were not disclosed, leaving some uncertainty about overall performance.
Management Promises & Guidance
Analysts are generally optimistic about Zimmer Biomet's upcoming earnings, expecting solid EPS and revenue figures. The consensus estimates suggest continued growth, but there are concerns about market conditions and competition.
Bull Case
If Zimmer Biomet beats EPS and revenue expectations, it could signal strong demand for its products and a successful execution of its growth strategy.
Bear Case
Conversely, if the company fails to meet expectations, it may raise concerns about its market position and operational challenges, leading to a negative reaction.
EPS
$1.86Earnings per share is a key indicator of the company's profitability and financial health.
Revenue
$2.1BRevenue growth reflects the company's ability to sell its products and expand its market share.
The print will turn on these two things.
Q1
Will EPS exceed the consensus estimate of $1.86?
A strong EPS figure would reinforce confidence in the company's profitability and operational efficiency.
Q2
What revenue figures will Zimmer Biomet report, and how do they compare to the $2.1B consensus?
Revenue performance is crucial for assessing the company's growth trajectory and market demand.
Why consensus could be wrong
The Street may underestimate the impact of new product launches and operational improvements that could drive better-than-expected results this quarter.
Supporting Evidence
The company has a strong track record of beating EPS estimates, with an 88% success rate in the last eight quarters.
Recent trends in the health care sector indicate increasing demand for surgical products, which could boost revenue.
Options pricing suggests a lower expected move compared to historical averages, indicating potential for a surprise.
Key Risk
If revenue significantly exceeds $2.1B, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
The market is evaluating Zimmer Biomet's ability to maintain growth amid competitive pressures and economic conditions.
Bull Confirmed If
An EPS of $1.90 or higher, along with revenue exceeding $2.1B, would confirm the bull case.
Bear Confirmed If
An EPS below $1.84 or revenue falling short of $2.0B would support the bear case.
Implied Move
±4.6%
Historical Avg
±6.5%
The options market is pricing in a moderate move around the earnings report, suggesting investors are anticipating some volatility.
Options are pricing ±4.6% while ZBH has averaged ±6.5% over the last 8 prints — setup is pricing cheap.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Zimmer Biomet beats expectations, history suggests the stock could rise by around 3.77%, confirming the strength of its market position.
In-Line / Cautious
An in-line report could lead to muted reactions, as investors await further commentary on future growth prospects.
Miss
If the company misses expectations, history indicates a potential drop of about 5.71%, raising concerns about its competitive standing.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
VERIZON COMMUNICATIO
Apr 27, 2026